The present text also includes those changes made in the Article 34 Amendment received by the EPO on July 5, 1999, and the amendments made under Article 34 of the PCT in the Reply to the Written Opinion, mailed March 9, 2000.

Applicant also respectfully requests the entry of the following amendments:

In the Specification: At page 8, line 19, please replace "Figures 26A-26C is" with --Figs. 26A, 26B and 26C are--. In the table on page 11, please amend the second line of SEQ ID NO:16 from "GAG AAG CCT GCT CTG CAT-3'" to - GAG AAG CCT GCT CTG CAT TTG-3' --. In the table on page 11, please amend the first line of SEQ ID NO:21 from "5' TTT CAT ATG ATA TAC TCC TTT GAT GGT CGA" to - 6' TTC CAT ATG ATA TAC TCC TTT GAT ĜGT CGA--. At page 15, line 3, please replace "Angiogenic Proteins" with - Angiogenic Proteins: Endostatin, Angiostatin and Restin, Using a Pichia Yeast Expression System---At page 15, line 4, please delete "its U.S. designation". At page 15, line 4, please replace "XX/XXX,XXX" with +09/ , , "Anti-Angiogenic Peptides and Methods of Use Thereof', by Vikas P. Sukhatme, filed June 8, 2000--. At page 17, lines 2-3, please delete "its U.S. designation". At page 17, line3, please replace "XX/XXX,XXX" with - 109/ Restin and Methods of Use Thereof', by Yikas P. Sukhatme, filed June 8, 2000--ÜŚ At page 17, line 4, please replace "Proteins" with f-Proteins: Endostatin, Angiostatin and Restin, Using a Pichia Yeast Expression System--. ale At page 17, line 4-5, please delete "its U.S. designation". At page 17, line 5, please replace "XX/XXX,XXX" with --09/ Producing Anti-Angiogenic Proteins", by Vikas P. Sukhatme, filed June 7, 2000--At page 26, line 21, please delete "its U.S. designation". At page 26, line 21, please replace "XX/XXX,XXX" with \$\frac{1}{1}\text{09}/_ Restin and Methods of Use Thereof', by Vikas P. Sukhatme, filed June 8, 2000--. At page 48, line 11, please replace "Proteins" with Proteins: Endostatin, Angiostatin and Restin, Using a Pichia Yeast Expression System--.